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Temporal inhibition of autophagy reveals
segmental reversal of ageing with
increased cancer risk
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Autophagy is an important cellular degradation pathway with a central role in metabolism as
well as basic quality control, two processes inextricably linked to ageing. A decrease in
autophagy is associated with increasing age, yet it is unknown if this is causal in the ageing
process, and whether autophagy restoration can counteract these ageing effects. Here we
demonstrate that systemic autophagy inhibition induces the premature acquisition of age-
associated phenotypes and pathologies in mammals. Remarkably, autophagy restoration
provides a near complete recovery of morbidity and a significant extension of lifespan;
however, at the molecular level this rescue appears incomplete. Importantly autophagy-
restored mice still succumb earlier due to an increase in spontaneous tumour formation.
Thus, our data suggest that chronic autophagy inhibition confers an irreversible increase in
cancer risk and uncovers a biphasic role of autophagy in cancer development being both
tumour suppressive and oncogenic, sequentially.
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Physiological ageing is a complex and multifaceted processassociated with the development of a wide array ofdegenerative disease states. While there is no accepted
singular underlying mechanism of ageing, a combination of
genetic, environmental and metabolic factors have been shown to
alter the ageing process1–3. As such, lifestyle and pharmacological
regimens have been proposed that may offer health- and or life-
span benefits4–6. However, despite chronological ageing repre-
senting the greatest risk factor for pathological conditions as
diverse as neurodegeneration, cancer, and cardiovascular disease,
there is a paucity of genetic mammalian models that allow for
dynamic modulation of key processes in mammalian ageing.
Autophagy is an evolutionarily conserved bulk cellular degra-
dation system that functions to breakdown and recycle a wide
array of cytoplasmic components from lipids, proteins and
inclusion bodies, to whole organelles (e.g. mitochondria).
Importantly a reduction in autophagic flux (the rate at which
autophagosomes form and breakdown cellular contents) is asso-
ciated with increasing age in mammals7. Evidence from lower
organisms suggests that autophagy inhibition can negate the
positive-effects of regimens that extend lifespan, such as calorie
restriction, rapamycin supplementation, and mutations in insulin
signalling pathways8–10.
In mice, the constitutive promotion of autophagy throughout
lifetime has been shown to extend health- and life-span in
mammalian models11,12. These studies have provided hitherto
missing evidence that autophagic flux can impact on mammalian
longevity and supports the notion that the pharmacological
promotion of autophagy may extend health-, and potentially life-
span, in humans. However, whether a reduction in autophagy is
sufficient to induce phenotypes associated with ageing, and
whether these effects can be reversed by restoring autophagy has
to date not been addressed. Considering that the therapeutic
window for pharmacological intervention to counteract ageing,
and age-related diseases, will be later in life (as opposed to from
conception), after autophagic flux has declined, it is critical to
understand how the temporal modulation (inhibition and
restoration) of autophagy may impact on longevity and health.
To address these questions, we use two doxycycline (dox)
inducible shRNA mouse models that target the essential autop-
hagy gene Atg5 (Atg5i mice) to demonstrate that autophagy
inhibition in young adult mice is able to drive the development of
ageing-like phenotypes and reduce longevity. Importantly we
confirm that the restoration of autophagy is associated with a
substantial restoration of health- and life-span, however this
recovery is incomplete. Notably the degree of recovery is seg-
mental, being dependent on both the tissue and metric analysed.
A striking consequence of this incomplete restoration is that
autophagy restored mice succumb to spontaneous tumour for-
mation earlier and at an increased frequency than control mice, a
phenotype not observed during autophagy inhibition alone. As
such our studies indicate that despite the significant benefit,
autophagy reactivation may also promote tumorigenesis in
advanced ageing context.
Results
Reduced lifespan in Atg5i mice. Previously, we have reported
the development of a highly efficient dox-inducible shRNA
mouse model targeting Atg5 (Atg5i)13 that phenocopies tissue-
specific Atg5 knockout (KO) mice and enables dynamic control
of autophagy (Supplementary Figs. 1 and 2). These mice lack
brain expression of the shRNA and as such do not suffer from the
lethal neurotoxic effects that characterise systemic autophagy
knockout mice14,15, and enable us to perform longitudinal studies
that were previously unachievable in vivo.
A common caveat of many mouse models is that genetic
manipulations are often present during embryogenesis. Thus, any
phenotypes that manifest are a combination of both develop-
mental and tissue homoeostasis effects. To avoid the generation
of these compound effects, Atg5i mice were aged until 8-weeks
(young adults) before being transferred to a dox-containing diet
and followed to assess overall survival. Atg5i mice on long-term
dox (LT-Atg5i) had a median survival of ~6 months on dox (Male
185 days; Female 207 days on dox) with no apparent sex bias
(Fig. 1a–c and Supplementary Fig. 3a).
In comparison with littermate controls, LT-Atg5i mice
experienced a progressive deterioration, initially presenting with
a reduction in coat condition within the first few weeks and a
reduction in weight gain that became more pronounced over the
life of the animal (Fig. 1d, e and Supplementary Fig. 3b). The
majority of mice eventually succumbed to a general morbidity
characterised by lethargy, piloerection, and a decrease in body
condition, wherein they have to be sacrificed. As previously
described with naturally aged colonies16, LT-Atg5i mice also
appeared susceptible to eye infections and ulcerative dermatitis,
the latter being primarily localised to the ears and neck and
ranging from mild to severe (Fig. 1f and Supplementary Fig. 3c,
respectively).
A singular cause of death in LT-Atg5i mice is difficult to
determine and it is most likely of multifactorial aetiology across
the cohort. At necropsy, all mice displayed hepatomegaly and
splenomegaly in comparison to age and sex matched controls,
consistent with phenotypes associated with tissue specific knock-
out mice17–19 (Supplementary Fig. 3d, e). Elevated serum Alanine
Aminotransferase (ALT) and reduced levels of serum albumin
were present throughout dox administration of Atg5i mice, yet
were altered further at the time of death only in a subset of
samples (Supplementary Fig. 3f, g, yellow circles). Consistent with
this, an increase in serum bilirubin levels was only observed at the
time of death within this same subset of mice (Supplementary
Fig. 3h, yellow circle). These data suggest that severe liver failure
occurs in only a fraction.
Interestingly serum creatinine levels, a marker of kidney
function, also displayed an increase only in a different subset of
LT-Atg5i mice at the time of death, although they were not
generally elevated during dox administration (Supplementary
Fig. 4a). Loss of autophagy also correlated with a general
thickening of the basement membrane and the presence of
sclerotic (Supplementary Fig. 4b) and enlarged glomeruli
(Supplementary Fig. 4c, d) in comparison with age-matched
tissue samples, indicative of degenerative kidney disorder. These
data suggest that, similar to the liver, systemic autophagy defect
causes age-associated degenerative alterations in kidney, yet only
a distinct subset progresses to renal failure on death. In addition
to this stochastic development of organ failure, LT-Atg5i mice
universally presented with cardiomyopathy (Supplementary
Fig. 4e). Histological examination highlighted the presence of
enlarged, degenerate and vacuolated cardiomyocytes, in addition
to the presence of cardiac fibrosis (Fig. 1g).
Together, our data suggest that, despite the stereotypic
premature death, LT-Atg5i mice suffered from a heterogeneous
set of tissue degenerative disorders that appear to have
contributed to an increase in mortality. Of note, there was no
evidence of overt tumour development in these mice at the time
of death.
Autophagy inhibition is associated with accelerated ageing.
After 4 months of dox treatment, all LT-Atg5i mice displayed
evidence of kyphosis that became progressively more pronounced
as the animals aged until death, whilst 16/28 LT-Atg5i mice
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displayed evidence of premature greying to varying degrees
(Fig. 1h). Furthermore, LT-Atg5i mice displayed evidence of
extramedullary hematopoiesis (Fig. 2a) and immune aggrega-
tions, commonly seen in aged mouse colonies, were also found in
the liver, lungs and kidneys but were generally absent in age
matched controls, although the incidence of these increased in
frequency with increasing age (Supplementary Fig. 5a–c).
As previously described in hematopoietic Atg5 KO mice, LT-
Atg5i mice also displayed an increase in cellularity of the
peripheral immune system18,20 (Fig. 2b, left) with a myeloid
skewing (Fig. 2c) reminiscent of age-associated chronic inflam-
mation. This ‘inflamm-ageing’ phenotype was further supported
by an increase in serum TNF and IL-6 in LT-Atg5i mice in
comparison with control (Fig. 2d). In addition, serum isolated
from LT-Atg5i mice displayed positivity of antinuclear antibodies
in 5/12 cases tested in comparison with 1/6 control mice, with the
predominant staining pattern being homogeneous and speckled,
implying a systemic autoimmune reaction in a subset of
autophagy inhibited mice (Supplementary Fig. 5e).
To determine whether the immune phenotypes were driven by
autophagy loss in the immune system or due to systemic
autophagy loss, we transplanted bone marrow from untreated
Control and Atg5i mice into irradiated wild-type C57BL/6 mice.
Subsequent doxycycline treatment for 4 months recapitulated
the myeloid skewing in peripheral blood in the mice with Atg5i
bone marrow (Fig. 2e) but with an apparent decrease in the
immune cellularity (Fig. 2b, right). Furthermore, in those mice,
there appeared to be a reduction in the donor-derived component
(i.e. Atg5i bone marrow-derived) of the peripheral blood
(Supplementary Fig. 5g). Largely consistent with a previous study
using Atg12 mutant mice18, combined these results suggest that
the general WBC expansion is driven by systemic autophagy loss,
while the myeloid skewing is immune cell intrinsic.
Skeletal muscle exhibits an age-related decline and autophagy
has been reported to be required for the maintenance of Pax7
positive satellite cells (myogenic precursors)21. In accordance, LT-
Atg5i mice displayed evidence of skeletal muscle degeneration
with the presence of smaller fibres, a reduction in the population
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Fig. 1 Autophagy inhibition decreases lifespan. LT-Atg5i mice on dox continuously from 2 months old display a reduced lifespan in comparison with LT-
Control as shown in survival graphs for combined (p < 0.0001) (a), male (p < 0.0001) (b), female (p < 0.0001) (c) (Mantel–Cox test). Median survival
(days on dox) and mice per group are indicated. During this period LT-Atg5i mice also display a reduced weight gain in both male (d) and female (e)
cohorts. f LT-Atg5i mice also display an increased frequency of skin inflammation and eye infections in comparison with age-matched LT-Control mice.
g Cardiac fibrosis was also evident in LT-Atg5i mice. Representative images of H&E and Massons Trichrome are shown. Scale bars, 100 μm. h Age-
matched skinned mice. LT-Atg5i mice show kyphosis (yellow dotted line traces the arch of the spine). They often displayed premature greying (dotted
rectangle). Arrows indicate the presence of inflammation.
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Fig. 2 LT-Atg5i mice present with accelerated aging phenotypes. a Extramedullary haematopoiesis is present in the spleens of LT-Atg5i mice in
comparison with age-matched controls. Scale bars, 100 μm. b 6-month-old LT-Atg5i mice (4 months dox treatment) display increased White Blood Cell
counts (WBC). Meanwhile, irradiated wild-type mice in receipt of uninduced bone marrow from Ctrl or Atg5i mice display a reduced WBC count after
4 months of dox treatment (unpaired two-tailed Welches t test, n= 5–6 per group). c Composition of the peripheral immune system in LT-Atg5i mice is
reminiscent of old control mice (n= 5–6 mice per group). d 6-month-old LT-Atg5i mice (4 months dox treatment) displayed increased serum levels of IL-6
and TNF (LT-Atg5i n= 5, LT-Ctrl n= 7; Mann Whitney Test). e Bone marrow transplantation of uninduced Ctrl and Atg5i bone marrow into irradiated
wild-type recipient mice after 4 months of dox treatment Atg5i recipient mice display a myeloid skewing. LT-Atg5i mice display alterations in skeletal
muscle after 4-month of dox treatment. LT-Atg5i mice display a significant difference in cross-sectional area (f) (n= 3 R-Ctrl and 3 R-Atg5i, unpaired two-
tailed Welch’s t test) and minimum feret size (g) (n= 3 R-Ctrl and 3 R-Atg5i, unpaired two-tailed Welch’s t test). LT-Atg5i mice also display a decrease in
Pax7 nuclear positivity per fibre (h), an increase in central nucleation (i), and positivity for the mitochondrial marker TOM20 (j), as determined by
tissue immunofluorescence (unpaired two-tailed Welches t test; n= 3 R-Ctrl and 3 R-Atg5i). Error bars indicate standard deviations. *p < 0.05; **p < 0.01,
***p < 0.001.
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of Pax7 positive satellite cells, and an increase in central
nucleation in comparison with age-matched littermate control
mice (Fig. 2f–i, Supplementary Fig. 6a, b). Central nucleation
represents muscle fibre regeneration after acute muscle injury but
an increase in basal frequency of centrally nucleated myofibres is
also a sign of sarcopenia at geriatric age both in mice and
human22. In addition, LT-Atg5i muscle fibres displayed increased
staining positivity for the mitochondrial marker Tom20 indica-
tive of increased mitochondrial mass and a reduction in
autophagy mediated turnover (Fig. 2j).
The accumulation of senescent cells is considered a key marker
of chronological ageing. Autophagy has been reported to have
context dependent and sometimes opposing roles during cellular
senescence: typically basal autophagy is considered to promote
fitness and its loss may promote senescence, whereas in
oncogene-induced senescence, autophagy may be important for
the establishment of senescent phenotypes23–26. To determine if
the systemic loss of basal autophagy is sufficient to drive the
establishment of cellular senescence in vivo, we performed
western blotting across a number of tissues from 4-month dox
treated LT-Atg5i mice and found an increased staining pattern
for key senescence markers (i.e. p16, p21, and p53) (Fig. 3a–c and
Supplementary Fig. 6c). In addition, whole mount senescence-
associated beta-galactosidase staining from 6-month treated livers
highlighted a marked increase in staining patterns in comparison
with LT-Control mice (Fig. 3d). Histologically, nuclear accumu-
lation of p21 was also evident, particularly in hepatocytes with
enlarged morphology (Fig. 3d). Furthermore LT-Atg5i mice
display a significant increase in both the abundance and
frequency of telomere-associated γ-H2AX foci (TAF) in liver,
lung and heart tissue (Fig. 3e, f and Supplementary Fig. 6d, e).
TAF represent persistent damage in telomeric regions, indepen-
dent of length, that are resistant to repair machinery and have
been shown to correlate with senescence, increasing age and
mitochondrial dysfunction27–29. The increase in TAF abundance
therefore reinforces the notion that mice exhibit age acceleration
upon systemic autophagy reduction.
Of note, similar gross phenotypic results were also seen in mice
with a second hairpin targeting Atg5 (LT-Atg5i_2). LT-Atg5i_2
mice display evidence of premature ageing-like phenotypes
(Supplementary Fig. 7a–c), however the appearance of these
phenotypes was delayed in comparison with LT-Atg5i mice,
seemingly due to a hypomorphic phenotype. Accordingly, these
mice displayed the accumulation of p62/Sqstm1 and LC3 in
multiple tissues but at lower levels in comparison with LT-Atg5i
mice, and did not display phenotypes associated with complete
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Atg5 knockout mice, including hepatomegaly and splenomegaly
(Supplementary Fig. 7d–f). These findings in particular are
important as they establish that the reduction in longevity and
presence of ageing phenotypes is not dependent on the
hepatomegaly and splenomegaly phenotypes encountered in the
original LT-Atg5i mouse strain with the highest degree of
autophagy inhibition.
Combined these data support a role for basal autophagy in
maintaining tissue and organismal homoeostasis and provide
evidence that causally links autophagy inhibition to the induction
of ageing-like phenotypes in mammals.
Autophagy restoration partially reverses ageing phenotypes.
We next sought to determine whether autophagy restoration
alone is able to reverse the ageing-like phenotypes by removing
dox from the diet. 8-week old Atg5i and control mice treated with
dox for 4 months, the point at which they universally presented
with kyphosis, were switched back to a diet absent of dox leading
to a restoration in Atg5 levels and autophagy (termed R-Atg5i
cohort) (Fig. 4a, b and Supplementary Fig. 8a)13. Interestingly,
while p16 levels reduced in the livers R-Atg5i mice, they still
appeared elevated in comparison with age-matched control mice
4-months post dox removal (Fig. 4b). This is in contrast to the
kidney that exhibited only a mild increase in p16 that was mostly
reversed upon autophagy restoration. While further systematic
analyses would be required, the data suggest a differential sus-
ceptibility to autophagy inhibition across organs.
An increase in chronological age is generally associated with
the deviations in multiple health parameters that when measured
can be combined into a clinical ‘frailty-score’30. As expected, R-
Atg5i mice displayed an initial increase in their frailty scores
during autophagy inhibition in comparison with littermate
controls, yet once mice have been switched back to a diet absent
of dox, the frailty scores displayed a significant decrease over the
next 4 months (Fig. 4c, Supplementary Movie 1). In contrast, LT-
Atg5i mice treated on dox for 6 months (median survival is
around ~6 months on dox) continued to display a significant
difference in their frailty scores, while almost all LT-Atg5i mice
had already succumbed by 8-months (Fig. 4c). A similar increase
in frailty was also noted in the LT-Atg5i_2 cohorts (Supplemen-
tary Fig. 7b). The penetrant kyphosis phenotype was largely
irreversible, however 3/26 R-Atg5i mice did show evidence of
recovery from kyphosis, while no mice displayed a reversal of the
greying phenotypes. As such, while autophagy inhibition in vivo
appears to promote frailty, autophagy restoration is seemingly
able to substantially reverse this effect.
Remarkably the profound immune-associated phenotypes that
we observed in autophagy-deficient LT-Atg5i mice were reversed
in R-Atg5i mice. Serum markers of inflammation and white blood
cell counts were indistinguishable between R-Atg5i and R-
Control mice (Fig. 4d, e and Supplementary Fig. 8b). However,
it should be noted that, in aged R-Atg5i mice removed from dox
for 8 months (14 months old), there was a trend towards a larger
red blood cell distribution width (RDW), which has previously
been linked to a range of diseases and an increased risk of acute
myeloid leukaemia (AML) (Fig. 4f)31. In addition, R-Atg5i livers
displayed a complete reversal of hepatomegaly and serum ALT
levels (Supplementary Fig. 8c, d). The kidneys of R-Atg5i mice
appeared to recover from autophagy inhibition and lacked
evidence of sclerotic and enlarged glomeruli (Supplementary
Fig. 8e–g). Consistently, serum albumin levels displayed evidence
of normalisation, although there was still a trend for reduced
levels in R-Atg5i mice at the time point tested, suggesting that
liver and/or kidney functions are largely recovered, if not
completely (Supplementary Fig. 8h).
Similarly, the protein aggregation marker p62/SQSTM1 in the
liver appeared much reduced in R-Atg5i mice in comparison to
the LT-Atg5i mice, yet a small but substantial number of cells still
exhibited a marked accumulation of p62 aggregation in R-Atg5i
mice that had been off dox for 4 months (Fig. 5a). In addition, R-
Atg5i livers were also found to contain the presence of ceroid-
laden macrophages and lipofuscin positivity, pigments known to
increase with age and not seen in age-matched controls mice
(Fig. 5b). Importantly, and in accordance with this partial
restoration phenotype, molecular markers of ageing such as TAF
also remained significantly elevated in R-Atg5i mice (Fig. 5c).
This is consistent with the persistent nature of telomeric DNA
damage, which is reported to be irreparable27,32. Together with
other senescence markers (Fig. 4b), these data suggest that a
portion of the cellular damage caused by a chronic block in
autophagy is irreversible.
Analysis of skeletal muscle from R-Atg5i mice, with autophagy
restoration, suggests that muscle fibre size, morphology, and
satellite cell frequency display no sign of recovery 2 months post
dox removal (Fig. 5d–f and Supplementary Fig. 6b). However,
central nucleation frequency was dramatically reduced and
comparable with control (Fig. 5g). As expected with Atg5
restoration, Tom20 positivity appeared similar to control levels
(Fig. 5h). In addition, the cardiac fibrosis observed LT-Atg5i mice
appears to still be present 4 months post dox removal in R-Atg5i
cohorts (Supplementary Fig. 9c). Together these data suggest that
autophagy restoration may have tissue and pathology specific
limitations in the capacity to recover from the tissue and cellular
damage induced upon its inhibition. Crucially, whilst some
tissues, such as the liver, appear to recover, they are still exhibit
age-associated pathologies at the molecular level.
Accelerated tumour development in R-Atg5i mice. As R-Atg5i
mice displayed some evidence of organismal rejuvenation and an
increase in overall health, we sought to determine if autophagy
restoration is able to reinstate natural longevity to the level seen
in littermate control mice, or whether the damage accumulation
impacting on lifespan was irreversible. Remarkably, the life-span
of R-Atg5i mice was significantly extended in comparison with
LT-Atg5i mice (median survival 493 days versus 185 days since
treatment began, respectively), while it was still significantly
shorter than the R-Control cohorts (Fig. 6a). In marked contrast
to LT-Atg5i mice, the cause of death was predominantly asso-
ciated with the development of tumours with an increased fre-
quency and at earlier timepoints (Fig. 6b, c). These tumours
display no evidence of continued autophagy inhibition via
immunohistochemical (IHC) analysis (Fig. 6d). Of note a whole-
body mosaic Atg5 knockout mouse model has been previously
reported to only develop liver adenomas but without any
malignant tumours33. Together, our data suggest that a tempor-
ary period of autophagy inhibition may be enough to induce
irreversible cellular damage, which might facilitate tumour
development cooperatively with the restoration of autophagy.
Discussion
While the rate of autophagic flux is believed to decrease with
advancing age and has been postulated to be a driver of ageing in
multicellular organisms, evidence in mammals has been limited
to the role of autophagy in maintaining stem cell populations18,21.
Such systemic organismal studies have been impossible to con-
duct owing to the embryonic or neonatal lethality and, in adult
mice, rapid neurotoxicity, which accompany systemic autophagy
ablation14,34. The temporal control and lack of brain shRNA
expression afforded by the Atg5i model have enabled us to cir-
cumvent these barriers, and separate developmental from tissue
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homoeostatic effects that cannot be distinguished in ageing
models based on constitutive or in utero genetic modifications.
In addition, it should be noted that whilst the LT-Atg5i model
leads to a dramatic reduction in Atg5 levels, with phenotypic
consequences of autophagy inhibition being evident (including
splenomegaly, hepatomegaly, LC3-I and p62 build-up), they
certainly retain some levels of autophagic flux, distinguishing
them from the Atg5 KO models. Of note the second hairpin
mouse model, LT-Atg5i_2 displays a reduction in Atg5 levels but
with a reduced build-up of LC3 and p62, as determined by IHC,
and no evidence of hepatomegaly and liver dysfunction, sug-
gesting that this model is hypomorphic. Hypomorphic models
may more closely recapitulate the aetiology of human disease,
wherein insufficient autophagic flux, not complete block is
associated with pathogenesis and ageing. In addition, the estab-
lishment of premature ageing phenotypes in the LT-Atg5i_2
model, without the overt tissue damage (e.g. hepatomegaly),
reinforces that reduced autophagy activity, not the liver damage,
is the primary driver. However, the widespread perturbation of
autophagy across multiple tissues, and the associated dysfunction
that accompanies it, almost certainly contributes to the acceler-
ated ageing phenotypes.
Our findings support the theory that a reduction in autophagy
is sufficient to induce several molecular and phenotypic char-
acteristics associated with mammalian ageing, including the
development of age-associated diseases and a reduction in long-
evity. Here it is notable that our Atg5i mice phenocopy other
models of ageing driven by the accumulation of damage and in
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particular mitochondrial dysfunction35,36, however it remains to
be seen whether mitochondrial function is altered in this setting.
In addition, we cannot rule out synergistic effects of doxycycline
side-effects with autophagy inhibition, as such comparison with
other inducible models would be required to exclude this
possibility.
Several health and life-span extending regimens in mammals,
such as calorie restriction or pharmacological modulation, have
been posited to exert their effects through the regulation of
autophagy7,37. However, these effects are also pleiotropic in
nature and alter a multitude of cellular processes, making it
impossible to deconvolute and ascribe the role of autophagy in
these settings. Whilst recent genetic models that promote
autophagic flux continuously throughout life have demonstrated
an extension of health- and life-span in mammalian systems11,12,
it is unclear if the damage established by a loss of autophagy is
sufficient for age acceleration and can be reversed. If therapeutic
regimens in humans are to be established later in life, once
autophagy-associated damage has accumulated, ascertaining the
capacity for autophagy restoration to repair this damage is cri-
tical. In our model, systemic inflammation and frailty scores
displayed a marked improvement upon autophagy restoration,
which resulted in increased survival. However, while some tissues
(i.e. liver and heart) displayed macroscopic normalisation, further
analysis highlighted the persistence of pathological phenotypes.
Our results indicate that markers of ageing such as TAF, or
macroscopic phenotypes such as greying and kyphosis may not
fully recover. It should also be noted that we have chosen a late
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time-point to restore autophagy as this provided a clear and
ubiquitous distinction between control and autophagy inhibited
mice, shorter time points or intermittent dosing regimens may
display further heterogeneity in damage and recovery phenotypes.
Our unexpected finding, that the temporal inhibition of
autophagy predisposes to increased tumour development, pro-
vides a potential genetic explanation for the context-dependent
role of autophagy in tumorigenesis:38,39 i.e. autophagy can be a
tumour suppressor33,40,41 or a tumour promoter42–44. The irre-
versible damage induced by autophagy inhibition (e.g. genomic
instability), might confer tumour susceptibility, while autophagy
activity is perhaps required for actual malignant transformation.
The clinical implication of our data is not limited to the advanced
age state. As some pathophysiological states, such as obesity, are
associated with an insufficient level of autophagy45, it would be
interesting to determine if obese individuals retain an increased
risk of tumour development even upon weight loss, in compar-
ison with never obese populations.
Methods
Atg5i mouse maintenance and aging. The generation and initial characterisation
of the Atg5i transgenic line have previously been described in detail13. Mice were
maintained on a mixed C57Bl/6 × 129 background with littermate controls used in
all experiments. All experimental mice were maintained as heterozygous for both
the shRNA allele and CAG-rtTA3 alleles, whereas control littermates were lacking
one of the alleles. Guide sequences were as follows: Atg5i (Atg5_1065) TATGAAG
AAAGTTATCTGGGTA13; Atg5i_2 (Atg5_1654) TTATTTAAAAATCTCTCACT
GT. Atg5_1654 was chosen after an initial screen for shRNA knockdown efficiency
wherein it displayed the second highest efficiency of knockdown13. The shRNA
guides in a miR-E design were inserted downstream of the Col1a1 locus via
recombinase-mediate cassette exchange which enables efficient targeting of a
transgene to a specific genomic site 500 base pairs downstream of the 3′UTR in
D34 ES cells. Mice were maintained in a specific pathogen-free environment under
a 12-h light/dark cycle, having free access to food and water. These mice were fed
either a laboratory diet (PicoLab Mouse Diet 20, 5R58) or the same diet containing
doxycycline at 200 ppm (PicoLab Mouse Diet, 5A5X). For this study mice were
aged for 2 months before doxycycline administration in the diet. Mice were enroled
either to time-point study groups or long-term longevity cohorts (LT- and R-
groups). Experienced animal technicians checked mice daily in a blinded fashion,
and additionally mice were weighed and hand-checked on a weekly basis. Mice
found to be of deteriorating health were culled under the advice of senior animal
technicians if displaying end of life criteria. These signs include a combination of
(1) hunched body position with matted fur, (2) piloerection, (3) poor body con-
dition (BC) score (BC1 to 2), (4) failure to eat or drink, (5) cold to touch, and or (6)
reduced mobility, including severe balance disturbances and ataxia. In accordance
with UK home office regulations any mice suffering a 15% loss of body weight were
also considered to be at an end-point. Note that for LT- longevity cohorts a portion
of control mice were culled to generate age-matched littermate control tissue.
These mice are marked as censored events on the survival curve. For analysis, mice
were treated as alive up to the point of their removal from the study where they are
considered lost to follow-up and are not included in the calculations of median
longevity. All experiments were performed in accordance with national and
institutional guidelines, and the ethics review committee of the University of
Cambridge approved this study.
Frailty scoring. Clinical frailty scoring was determined using the previously
published frailty index30. A blinded researcher and animal technician performed all
frailty scores independently within the same 48 h period and scores were compared
afterwards to ensure accuracy of phenotype scoring. The method is based on
scoring 31-parameters as Normal (scores 0), Mild (scores 0.5), or Severe (scores 1).
The total score for a mouse is then divided by the number of metrics being
analysed to create a total frailty score for the animal. This includes alopecia, loss of
fur colour, dermatitis, loss of whiskers, coat condition, presence of tumours, dis-
tended abdomen, kyphosis, tail stiffening, gait disorders, tremors, forelimb grip
strength, body condition score, vestibular disturbance, hearing loss, presence of
cataracts, alterations to corneal opacity, eye swelling or discharge, sunken eyes (one
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or both), vision loss, menace reflex, nasal discharge, malocclusions, rectal prolapse,
prolapse (vaginal, uterine, or penile), diarrhoea, altered respiratory rate, alterations
to mouse grimace, piloerection, body temperature and weight.
Doxycycline serum measurements. An LC-MS/MS assay was developed for the
analysis of doxycycline in mouse plasma with demeclocycline as an internal
standard.
Doxycycline Hyclate (Sigma-Aldrich, 108M4031V) and Demeclocycline HCl
(Sigma-Aldrich, D61140) were purchased (Sigma-Aldrich) and individual stock
solutions were prepared in water: methanol: formic acid (9:1:0.1) to a concentration
of 1 mg/mL of the free base. Doxycycline calibration standards were prepared in K2
EDTA mouse plasma, with a final range of 0.5–125 ng/mL. Ten microliter of
sample was mixed with 10 µL of internal standard (25 ng/mL in water:methanol:
formic acid (9:1:0.1)) and extracted with 100 µL of ethyl acetate. The organic layer
was transferred, evaporated and reconstituted in 50 µL of water:methanol:formic
acid (9:1:0.1). 5 µL was injected into the LC-MS/MS system. Chromatography was
performed on a Shimadzu Nexera X2 UHPLC system with a Phenomenex Luna
Omega C18 100 Å 1.6 µm 100 × 2.1 mm column at 35 °C using a 0.1% formic acid
in water/0.1% formic acid in acetonitrile gradient at 0.4 mL/min over 5 min.
Doxycycline and demeclocycline had retention times of 1.87 and 1.81 min
respectively. Doxycycline produced an unavoidable split peak, but it was
reproducible, consistent and did not affect the precision or accuracy. The liquid
chromatograph was coupled to a Sciex Triple TOF 6600 mass spectrometer
operated using positive electrospray ionisation and enhanced mass high sensitivity
product ion scan mode for doxycycline (m/z 445.2–28.1360) and demeclocycline
(m/z 465.07–448.0810). Data acquisition was controlled via Sciex Analyst TF
1.7.1 software and data processed using Sciex MultiQuant 3.0.2 with a processing
mass peak width of 0.05 Da for both doxycycline and demeclocycline (i.e.
428.1360 Da ± 0.025 and 448.0810 Da ± 0.025 respectively). A linear 1/x2 weighted
regression using the peak area ratio of doxycycline and demeclocycline was used to
construct the calibration curve. Precision and accuracy were within the predefined
criteria of ±20%.
Pathology and Immunohistochemistry. Explanted tissues were fixed in 10%
neutral-buffered formalin solution for 24 h and transferred to 70% ethanol. Tissues
were embedded in paraffin, cut in 3 μm sections on poly-lysine coated slides,
deparaffinized, rehydrated, and stained with H&E. The PAS, Congo Red and
Massons Trichrome histochemical stains were performed according to established
protocols. An experienced pathologist reviewed all histology blinded for evidence
of tumours and tissue pathologies. For immunohistochemistry and tissue immu-
noflourescence formalin-fixed paraffin-embedded samples were de-waxed and
rehydrated. For anti-P21 (Santa Cruz, SC-6246; 1:500), and anti-TOM20 (Santa
Cruz SC-11415, 1:500) staining antigen unmasking was performed with citrate
buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6) in a pressure cooker for
5 min at 120 °C. For P21 exogenous peroxidases were quenched in 3% H2O2/PBS
for 15 min and the remaining steps were performed according to Vector Labs
Mouse on Mouse staining kit (MP-2400). The remaining antibodies were used at
the following concentrations and ran on the Leica Polymer Detection system
(DS9800) with the Leica automated Bond platform: Anti-SQSTM1 (Enzo, BML-
PW9860; 1:750), anti-KI67 (Bethyl Laboratories, IHC-00375; 1:1000), Anti-LC3
(Nanotools, LC3-5F10 0231-100, 1:400). Anti-CD45-B220 (R&D Systems,
MAB1217, 0.67 µg/mL), Anti-CD3 (Dako, A0452, 1:1000), Anti-F4/80 (Serotec,
MCA497, 1:20).
For CD45-B220, CD3, F4/80 quantification whole tissue sections were analysed
using ImageScopeTM (Leica Biosystems). For CD45-B220 and CD3 the percentage
positive nuclei were determined. For F4/80 a percentage-positive pixel count was
quantified.
For Tom20 analysis the intensity of signal per entire muscle section was
determined and an average measurement of intensity per unit area calculated.
Samples were then plotted as a fold increase relative to the average intensity per
unit of control muscle sections
For kidney glomeruli size tissue sections were analysed using ImageScopeTM
(Leica Biosystems) and the cross-sectional area of ten glomeruli in the renal cortex
was reported per sample.
Electron microscopy. Briefly, each mouse was perfused using a Peristaltic Pump
P-1 (GE Healthcare) with 50 mL of wash buffer (10 mM PIPES pH 7.4, 137 mM
NaCl, 2.7 mM KCl, 2.5 mM CaCl2, 19.4 mM glucose, 10 mM sodium nitrite,
0.075 mM PVP10), followed by 100 mL of fixative (2% glutaraldehyde/2% For-
maldehyde in 0.1 M PIPES pH 7.4 (+2 mM CaCl and 0.075 mM PVP10)). After
perfusion tissue was dissected and cut into 1 mm3 before being placed in fixative
overnight. These were washed in 0.05 M Na cacodylate buffer (5×), before osmi-
cation for 3 days at 4 °C (1% OsO4, 1.5% potassium ferricyanide, 0.05M Na
cacodylate buffer pH 7.4). This was followed with 5× washes in deionized water, a
second round of osmication (1 h at room temperature; 2% OsO4 in DIW), and 5×
washes in DIW, before samples were passed through a dehydration gradient (3 ×
50%, 3 × 70%, 3 × 95%, 3 × 100% ethanol for 5 min each). Samples were then
dehydrated in 2 × 5 min washes of 100% acetone, followed by 3 × 5 min washes of
100% acetonitrile. Samples were next placed in Quetol resin mix (12 g Quetol 651,
15.7 g NSA, 5.7 g MNA, 0.5 g BDMA) added to equal volumes of 100% acetonitrile
for 24 hrs at room temperature. After which samples were placed into pure Quetol
resin mix (with BDMA) for 5 days, with fresh resin mixed added daily. Embedded
samples were placed into moulds and incubated at 60 °C for 48 h before being
sectioned (~80 nm) on an ultramicrotome (Leica Ultracut) and mounted onto 400
mesh bare copper grids. TEM was performed on a FEI Tecnai G20 electron
microscope run at 200 keV accelerating voltage and using a 20 μm objective
aperture to improve contrast.
Western blotting. Tissue samples were homogenised with the Precellys 24 tissue
homogeniser in Laemmli buffer and samples ran on 12.5 or 15% gels. Protein was
transferred to PVDF membranes (Immobilon, Millipore), which was subsequently
blocked for 1 h at room temperature (5% milk solution in TBS-Tween 0.1%) before
incubating with primary antibody at 4 °C overnight. An appropriate HRP-
conjugated secondary antibody was incubated at room temperature for 1 h. Wes-
tern blots were visualised with chemiluminescence reagents (Sigma, RPN2106).
Antibodies were used at the following concentrations: Anti-ATG5 (Abcam,
ab108327; 1:1000), anti-LC3 (Abcam, ab192890; 1:1000), anti-ACTIN (Santa Cruz
Biotechnology, I-19; 1:5000 [no longer commercially available]), anti-P53 (Cell
Signalling Technologies, Clone 1C12; 1:1000), anti-P21 (Santa Cruz, SC-6246;
1:1000), anti-Histone H3 (Abcam, ab1791; 1:5000), anti-P16 (Santa Cruz, SC-1207;
1:1000), anti-HMGA1 (Abcam, ab129153; 1:1000), anti-NBR1 (Abcam, ab55474;
1:1000).
Blood and serum analysis. Whole blood composition was performed using the
Mythic Haematology Analyser to determine whole blood counts, immune com-
position, and RDW. Mouse cytokines were determined using a cytometric bead
array (BD Biosciences, Catalogue number: 552364). Sera isolated from mice were
analysed by the Core Biochemical Assay Laboratory (CBAL), Cambridge, UK for
Alanine Transferase (Siemens Healthcare), Albumin (Siemens Healthcare), Bilir-
ubin (Siemens Healthcare), and Creatinine (Siemens Healthcare) using automated
Siemens Dimension RxL and ExL analysers.
Anti-nuclear antibody detection in HEp-2 cells. Serum samples from control and
Atg5i mice were diluted 1:50, 1:100 and 1:200 with PBS. The diluted sera were
incubated with human epithelial cell (HEp-2) substrate slides (Kallestad Bio-Rad
#26102) for 30 min at room temperature in a humidified chamber. After 3 × 5 min
washes in PBS, samples were blocked with 5% normal goat serum for 1 h and
subsequently incubated with AlexaFluor488 conjugated goat anti-mouse IgG
antibody in 5% normal goat serum for 1 h. The slides were then washed as pre-
viously and were evaluated using fluorescence microscopy. Interpretation of
positivity and grading were performed using the ×20 objective while evaluation of
pattern was performed using the ×40 objective.
Telomere associated DNA damage foci (TAF). Formalin-fixed paraffin-
embedded liver sections were hydrated by incubation in 100% Histoclear, 100, 95
and 2 × 70% methanol for 5 min before washed in distilled water for 2 × 5 min. For
antigen retrieval, the slides were placed in 0.1 M citrate buffer and heated until
boiling for 10 min. After cooling down to room temperature, the slides were
washed 2× with distilled water for 5 min. After blocking in normal goat serum
(1:60) in BSA/PBS, anti-γ-H2A.X primary antibody (Cell Signalling Technologies,
S139; 1:250) was applied and incubated at 4 °C overnight. Slides were washed 3× in
PBS, incubated with secondary antibody for 30 min, washed three times in PBS and
incubated with Avidin DCS (1:500) for 20 min. Following incubation, slides were
washed three times in PBS and dehydrated with 70, 90 and 100% ethanol for 3 min
each. Sections were denatured for 5 min at 80 °C in hybridisation buffer (70%
formamide (Sigma), 25 mM MgCl2, 1 M Tris pH 7.2, 5% blocking reagent (Roche)
containing 2.5 μg mL−1 Cy-3-labelled telomere specific (CCCTAA) peptide nuclei
acid probe (Panagene), followed by hybridisation for 2 h at room temperature in
the dark. The slides were washed with 70% formamide in 2 × SSC for 2 × 15 min,
followed by 2 × SSC and PBS washes for 10 min. Sections were incubated with
DAPI, mounted and imaged. In depth Z stacking was used (a minimum of 40
optical slices with ×100 objective) followed by Huygens (SVI) deconvolution.
Senescence associated beta-galactosidase staining. Whole tissue samples were
washed in PBS (pH5.5) before being fixed in 0.5% glutaraldehyde overnight and
washed 2 × 15 min in PBS (pH5.5) at 4 °C. SA-β-gal activity was assessed after
incubation in X-Gal solution for 90 min at 37 °C.
Muscle morphopmetric analysis. Mice were sacrificed at the time points
described and dissected muscle was rapidly frozen in liquid nitrogen cooled
isopentane to maintain structure and minimise tissue artifacts. Experimental
mice and age-matched littermate controls were isolated at the same time to
ensure processing was consistent between groups. Frozen muscles were equili-
brated in a cryostat chamber to −20 °C and cryosections 10-μm thick were then
cut from the middle third of the sample and collected on poly-L-lysine (0.5 mg/
mL)–coated glass slides. Sections were allowed to air dry and were then frozen at
−80 °C prior to use. Samples were brought to 4 °C on ice and fixed in a 4% w/v
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0.45 mm filtered paraformaldehyde solution in 1 × PBS for 15 min at 4 °C. PFA
was removed by three 5 min washes in 1 × PBS, then blocked in 10% v/v serum
in 1 × PBST (0.01% Tween-20) for 1 h at RT. Primary anti-dystrophin antibody
(Abcam, ab15277, 1:1000) was then applied in 1 × PBST containing 10% v/v
serum for 2 h at room temperature. Three 5-min PBST washes were applied
before secondary antibody conjugated to Alexa Fluor 647, with DAPI at 1:1000,
incubation in PBST and 10% v/v serum for 1 h at room temperature. Sections
were finally washed three times for 15 min before mounting in Vectorshield
Antifade Mounting Medium (Vector Labs). Whole cross-sections of TA muscles
were produced via montaged ×40 magnification tile scans (Zeiss Axio Z1
Widefield system). Morphometric analysis was performed using Fiji open source
software. A macro was developed to sequentially (i) subtract background com-
ponents to minimise noise that could interfere with further analysis; (ii) apply a
thresholding filter for fibre border detection; (iii) generate a mask of the muscle
fibre borders using the analyse particles function, simultaneously eliminating
stray “non-border” signals; and (iv) overlay threshold-delimited nuclei over the
border mask, before another analyse particles command was used to measure
morphometric variables including “area” and “minimum Feret diameter.” as
previously described46. Simultaneous DAPI nuclear stain was used for central
nucleation count. PAX7 counts were performed manually in a blinded fashion, a
satellite cell was defined as having a PAX7 positive nuclei within a LAMININ cell
border staining. For immunostaining the following antibodies were used anti-
PAX7 PAX7 (DSHB, PAX7, 1:50), after pre-treatment with Vector Labs Mouse
on Mouse Blocking Reagent (MKB-2213) according to manufacturer’s instruc-
tions and anti-LAMININ (Abcam, ab11576, 1:1000).
Bone marrow transplantation. Atg5i mice were backcrossed 11 times to C57BL/6.
At 2-month bone marrow was harvested from male Atg5i and littermate controls
(containing only one allele of the two-allele system). 2 × 106 cells were transplanted
into irradiated, female C57BL/6 mice (2 × 5 gy 12 h apart, transplantation occurred
24 h after the first dose). Mice were left for 1 month to enable engraftment and
subsequently treated for 4 months with doxycycline at 200 ppm via their food
(PicoLab Mouse Diet, 5A5X). After 4 months mice had frailty scores and blood
composition analysed as described above. Additionally, to test for chimerism DNA
was extracted from the blood (Qiagen DNeasy Blood & Tissue Kit) and PCRs
performed to distinguish DNA from male and female origin as described pre-
viously47. Briefly primers amplify Kdm5c (an X-linked gene; 331 bp) and Kdm5d
(a Y-linked gene; 302 bp). Whilst female mice produce only one band, males
produce two, an alteration in the ratio of the upper to lower band away from that
seen control DNA is indicative of altered chimerism.
Forward: 5′-CTGAAGCTTTTGGCTTTGAG-3′
Reverse: 5′-CCACTGCCAAATTCTTTGG-3′.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data and materials availability
All data and materials are available in the manuscript or upon request. Source data for
Figs. 3a–c and 4b, Supplementary Figs. 1b, 6c, and 8a are provided as a source data file.
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